Improving Survival in Myeloma Patients with High-Risk Cytogenetics through Tandem Transplant

This chapter delves into a Phase 2 study showcasing improved survival outcomes in myeloma patients with high-risk cytogenetics through tandem transplant and specific treatment regimens. Results demonstrate a high overall response rate, promising progression-free survival at 30 months, and successful tandem transplant completion in majority of patients.